Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Tasigna sales were up by almost 100% in one quarter with first-line clearance.
You may also be interested in...
Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia
Tasigna Beats Sprycel To First-Line CML Punch
Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)